Eisai files for Japanese approval of Biocompatibles' embolic beads
This article was originally published in Scrip
Executive Summary
Following the exercise of an option earlier this year, Eisai has now made an approval filing in Japan for a microspheric bead product licensed from Biocompatibles International, for the treatment of hepatocellular carcinoma (HCC).